Optimising Radiomics for MRI-based personalised cancer treatment

Fact Sheet

Project Information

REACT

Grant agreement ID: 739738

Project website ↗

DOI
10.3030/739738 ↗

Project closed

EC signature date
17 August 2017

Start date
17 November 2017

End date
16 November 2018

Funded under
INDUSTRIAL LEADERSHIP - Innovation In SMEs

Total cost
€ 147 212,50

EU contribution
€ 147 212,50

Coordinated by
PT THERAGNOSTIC BV
Netherlands

Objective

Although cancer survival rates have substantially improved in recent years, cancer is still among the leading causes of morbidity and mortality worldwide. The future of cancer treatment lies in early and better diagnosis and individually tailored treatments ('personalised medicine). ptTheragnostic, a company dedicated to the development of more effective, individualised therapies for cancer patients, is working on a breakthrough solution, Radiomics, that is able to revolutionise personalised cancer treatment. Radiomics is a quantitative image analysis technology that enables patient

stratification through the use of routinely acquired biomarkers. Being based on the evolution of hundreds of image-derived features over the course of treatment, Radiomics allows for more sensitive and robust identification of tumour types than currently possible. As MRI is recognised as one of the most promising techniques for the detection of cancer and spread of the disease, ptTheragnostic aims to align Radiomics with MRI. Despite the availability of a multi-disciplinary team at ptTheragnostic, they lack the required expertise and skills to implement Radiomics in the MRI market. Therefore, the goal of this project, REACT, is to hire a skilled associate with expertise in MRI and deep learning to establish this implementation. During the first 12 months, the associate will be responsible for managing the designed innovation track of Radiomics. This includes both technical and business tasks, amongst aligning the Radiomics software with MRI scanners and drafting a marketing strategy for Radiomics. The associate will follow various trainings in the oncology and business field. REACT may therefore open up new career possibilities in both the business and academic (oncology) field. In addition, REACT, will leverage the growth of ptTheragnostic by enabling Radiomics for MRI resulting in a significant increase in revenues (additional 50% in the first year) and increase in FTE (33%).

Fields of science (EuroSciVoc) ⓘ

social sciences > sociology > demography > **mortality**

medical and health sciences > clinical medicine > **oncology**

medical and health sciences > basic medicine > **pathology**

medical and health sciences > health sciences > **personalized medicine**

natural sciences > computer and information sciences > artificial intelligence > machine learning > **deep learning**

ⓘ

Programme(s)

H2020-EU.2.3. - INDUSTRIAL LEADERSHIP - Innovation In SMEs (MAIN PROGRAMME)
H2020-EU.2.3.2.2. - Enhancing the innovation capacity of SMEs

Topic(s)

INNOSUP-02-2016 - European SME innovation Associate - pilot

Call for proposal

[H2020-INNOSUP-2016-2017](#) ↗

[See other projects for this call](#)

Sub call

H2020-INNOSUP-02-2016

Funding Scheme

[CSA - Coordination and support action](#)

Coordinator

PT THERAGNOSTIC BV

Net EU contribution

€ 147 212,50

Total cost

€ 147 212,50

Address

OXFORDLAAN 55 BIOPARTNER BUILDING

6229 EV Maastricht

Netherlands

SME ⓘ

Yes

Region

Zuid-Nederland > Limburg (NL) > Zuid-Limburg

Activity type

Private for-profit entities (excluding Higher or Secondary Education Establishments)

Links

[Contact the organisation](#) ↗
[Participation in EU R&I programmes](#) ↗
[HORIZON collaboration network](#) 🤝

Last update: 10 March 2023

Permalink: https://cordis.europa.eu/project/id/739738

European Union, 2025